# Study of Huperzine A Sustained-Release Tablets in Patients With Alzheimer's Disease

> **NCT01282619** · PHASE2,PHASE3 · UNKNOWN · sponsor: **Shandong Luye Pharmaceutical Co., Ltd.** · enrollment: 390 (estimated)

## Conditions studied

- Alzheimer's Disease

## Interventions

- **DRUG:** Huperzine A
- **DRUG:** huperzine A
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01282619
- **Lead sponsor:** Shandong Luye Pharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2010-05
- **Primary completion:** 2012-06
- **Final completion:** 2012-06
- **Target enrollment:** 390 (ESTIMATED)
- **Last updated:** 2011-01-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01282619

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01282619, "Study of Huperzine A Sustained-Release Tablets in Patients With Alzheimer's Disease". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT01282619. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*